# Palbociclib

## Ibrance 125mg

| 藥物代碼 | OIBR |
| :--- | :--- |
| 適應症 | Breast cancer, advanced \(initial endocrine-based therapy\): Treatment of hormone receptor \(HR\)-positive, human epidermal growth factor receptor 2 \(HER2\)-negative advanced or metastatic breast cancer \(in combination with an aromatase inhibitor\) in postmenopausal women as initial endocrine-based therapyBreast cancer, advanced \(with disease progression following endocrine therapy\): Treatment of HR-positive, HER2-negative advanced or metastatic breast cancer \(in combination with fulvestrant\) in women with disease progression following endocrine therapy |
| 副作用 | &gt;10%: Central nervous system: Fatigue \(41%\), headache \(26%\), peripheral neuropathy \(13%\)Dermatologic: Alopecia \(18% to 22%\), skin rash \(17%\)Gastrointestinal: Nausea \(25% to 34%\), stomatitis \(25% to 28%\), diarrhea \(21% to 24%\), constipation \(20%\), vomiting \(15% to 19%\), decreased appetite \(16%\)Hematologic & oncologic: Neutropenia \(75% to 83%; grade 3: 48% to 55%; grade 4: 6% to 11%\), decreased absolute lymphocyte count \(81%; grade 3: 17%; grade 4: 1%\), anemia \(30% to 78%; grade 3: 3% to 5%; grade 4: ?1%\), leukopenia \(43% to 53%; grade 3: 19% to 30%; grade 4: ?1%\), thrombocytopenia \(17% to 23%; grade 3: 2%; grade 4: ?1%\)Infection: Infection \(47% to 55%\)Neuromuscular & skeletal: Weakness \(8% to 13%\)Respiratory: Upper respiratory tract infection \(31%\), epistaxis \(7% to 11%\)Miscellaneous: Fever \(13%\)1% to 10%:Cardiovascular: Pulmonary embolism \(1% to 5%\)Dermatologic: Xeroderma \(6%\)Gastrointestinal: Dysgeusia \(7%\)Hematologic & oncologic: Febrile neutropenia \(1%; grade 3: 1%\)Ophthalmic: Blurred vision \(6%\), increased lacrimation \(6%\), dry eye syndrome \(4%\) |
| 禁忌 | Hypersensitivity to palbociclib or any component of the formulation |
| 藥物保存方式 | 室溫 |
| 用法用量 | Breast cancer, advanced, initial endocrine-based therapy: Females \(HER-2 negative\): Oral: 125 mg once daily for 21 days, followed by 7 days off, repeat every 28 days \(in combination with continuous aromatase inhibitor therapy\); continue until disease progression or unacceptable toxicity. Breast cancer, advanced \(with disease progression following endocrine therapy\): Females \(HER-2 negative\): Oral: 125 mg once daily for 21 days, followed by 7 days off, repeat every 28 days \(in combination with fulvestrant \[and an LHRH agonist \(eg, goserelin\) if pre- or perimenopausal\]\); continue until disease progression or unacceptable toxicity. |
| 肝功能異常 | 需 調 整 劑 量  Severe impairment \(Child-Pugh class C\): Reduce dose to 75 mg once daily for 21 days, followed by 7 days off; repeat every 28 days. |
| 腎功能異常 | 無需調整劑量 |
| 懷孕用藥危分級 | 不可使用 |
| 孕期用藥建議 | Contraindicated |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | Contraindicated 哺乳期使用禁忌 |
| 附帶說明 | N/A |
| 注射劑給藥建議途徑 | N/A |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | N/A |

## Ibrance 125mg \(Sample\)

| 藥物代碼 | OIBR0 |
| :--- | :--- |
| 適應症 | Breast cancer, advanced \(initial endocrine-based therapy\): Treatment of hormone receptor \(HR\)-positive, human epidermal growth factor receptor 2 \(HER2\)-negative advanced or metastatic breast cancer \(in combination with an aromatase inhibitor\) in postmenopausal women as initial endocrine-based therapyBreast cancer, advanced \(with disease progression following endocrine therapy\): Treatment of HR-positive, HER2-negative advanced or metastatic breast cancer \(in combination with fulvestrant\) in women with disease progression following endocrine therapy |
| 副作用 | &gt;10%: Central nervous system: Fatigue \(41%\), headache \(26%\), peripheral neuropathy \(13%\)Dermatologic: Alopecia \(18% to 22%\), skin rash \(17%\)Gastrointestinal: Nausea \(25% to 34%\), stomatitis \(25% to 28%\), diarrhea \(21% to 24%\), constipation \(20%\), vomiting \(15% to 19%\), decreased appetite \(16%\)Hematologic & oncologic: Neutropenia \(75% to 83%; grade 3: 48% to 55%; grade 4: 6% to 11%\), decreased absolute lymphocyte count \(81%; grade 3: 17%; grade 4: 1%\), anemia \(30% to 78%; grade 3: 3% to 5%; grade 4: ?1%\), leukopenia \(43% to 53%; grade 3: 19% to 30%; grade 4: ?1%\), thrombocytopenia \(17% to 23%; grade 3: 2%; grade 4: ?1%\)Infection: Infection \(47% to 55%\)Neuromuscular & skeletal: Weakness \(8% to 13%\)Respiratory: Upper respiratory tract infection \(31%\), epistaxis \(7% to 11%\)Miscellaneous: Fever \(13%\)1% to 10%:Cardiovascular: Pulmonary embolism \(1% to 5%\)Dermatologic: Xeroderma \(6%\)Gastrointestinal: Dysgeusia \(7%\)Hematologic & oncologic: Febrile neutropenia \(1%; grade 3: 1%\)Ophthalmic: Blurred vision \(6%\), increased lacrimation \(6%\), dry eye syndrome \(4%\) |
| 禁忌 | Hypersensitivity to palbociclib or any component of the formulation |
| 藥物保存方式 | 室溫 |
| 用法用量 | Breast cancer, advanced, initial endocrine-based therapy: Females \(HER-2 negative\): Oral: 125 mg once daily for 21 days, followed by 7 days off, repeat every 28 days \(in combination with continuous aromatase inhibitor therapy\); continue until disease progression or unacceptable toxicity. Breast cancer, advanced \(with disease progression following endocrine therapy\): Females \(HER-2 negative\): Oral: 125 mg once daily for 21 days, followed by 7 days off, repeat every 28 days \(in combination with fulvestrant \[and an LHRH agonist \(eg, goserelin\) if pre- or perimenopausal\]\); continue until disease progression or unacceptable toxicity. |
| 肝功能異常 | 需 調 整 劑 量  Severe impairment \(Child-Pugh class C\): Reduce dose to 75 mg once daily for 21 days, followed by 7 days off; repeat every 28 days. |
| 腎功能異常 | 無需調整劑量  需調整劑量 |
| 懷孕用藥危分級 | 不可使用 |
| 孕期用藥建議 | Contraindicated |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | Contraindicated 哺乳期使用禁忌 |
| 附帶說明 | N/A |
| 注射劑給藥建議途徑 | N/A |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | N/A |

